FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma

WOODCLIFF LAKE, N.J., Aug. 8, 2013 -- (Healthcare Sales &Marketing Network) -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational compound (E7777) for cutaneous t-cell ly... Biopharmaceuticals, Oncology, FDAEisai, orphan drug, E7777, cutaneous t-cell lymphoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Ling YL, Huang X, Mitri G, Lovelace B, Pham, Knobler R, Li X, Gao X Abstract INTRODUCTION: The National Comprehensive Cancer Network and the European Organization for Research and Treatment of Cancer recommend extracorporeal photopheresis (ECP) as systemic therapy for cutaneous T-cell lymphoma (CTCL). OBJECTIVE: To investigate real-world use of ECP in CTCL patients in the US. METHODS: Data from the Truven MarketScan® database (2010-2015) were used to create a cohort of CTCL patients receiving systemic treatment. Multivariable regressions were performed to compare health care resource utilizatio...
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
(City of Hope) City of Hope recently received $7.5 million to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma. The NCI awarded $6.3 million over five years to City of Hope's Steven Rosen, M.D., and Christiane Querfeld, M.D., Ph.D., so they can develop improved therapies for the disfiguring, incurable cancer that affects about 3,000 new individuals per year. LLS gave the pair two grants totaling $1.2 million over three years.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Targeting epigenetic modifiers is effective in cutaneous T cell lymphoma (CTCL). However, there is a need for further improvement of this therapeutic approach. Here, we compared the mode of action of romidepsi...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Tags: Research Source Type: research
Authors: Wong HK PMID: 30863486 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Cutaneous T-cell lymphomas (CTCL) are a family of primary extranodal lymphomas of mature CD4+, skin-homing or skin-resident T-cells. In a significant fraction of CTCL patients the neoplastic CD4+ lymphocytes acquire extracutaneous tropism, and with disease progression, they disseminate to the lymph nodes, peripheral blood, and visceral organs. MicroRNA (miR)-based therapies are a newly emerging strategy for many types of diseases, including cancers. CTCL represents one of the disease indications for a clinical trial of miR inhibitor therapy, supporting further investigation of epigenetic dysregulation and miR-driven oncoge...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Original Article Source Type: research
While it’s hard not to notice the brilliant display of colors set off by a sunset over the water, we seldom consider the biological, or even psychological, benefits of light. “It is my belief that good quality light in our daily lives is far more important than we might think,” writes Karl Ryberg. In his new book, Living Light: The Art of Using Light For Health And Happiness, Ryberg brings us his life’s work — studying the obvious and not so obvious ways in which light affects us and how we can use light in our lives not only function better, but feel better. Light, we know, plays an important...
Source: Psych Central - Category: Psychiatry Authors: Tags: Book Reviews Disorders General Habits Psychology Seasonal Affective Disorder Self-Help Treatment artificial light Light therapy Living Light natural light Ryberg SAD Source Type: news
Monoclonal antibody therapies, such as alemtuzumab, brentuximab vedotin, and mogamulizumab, are showing promise for previously relapsed and refractory CTCL.American Journal of Clinical Dermatology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
lls J Abstract Cutaneous T-cell lymphoma is an uncommon group of non-Hodgkin's lymphoma primarily affecting the skin. It is comprised of a variety of entities with different clinical behaviours and prognosis. Mycosis fungoides is the commonest subtype, and Sézary syndrome is a much rarer form of cutaneous T-cell lymphoma. At this stage, control rather than cure is the goal of therapy, with particular emphasis placed on preserving quality of life. Our review of the efficacy, safety profile and accessibility of treatment modalities for mycosis fungoides/Sézary syndrome is a tailored guide for the clini...
Source: The Australasian Journal of Dermatology - Category: Dermatology Authors: Tags: Australas J Dermatol Source Type: research
CONCLUSIONS: These findings can be explained by a model where malignant transformation takes place during early T-cell development giving rise to circulating pre-malignant clones which home to the skin producing clinically apparent lesions of cutaneous lymphoma. Therapeutic strategies in T-cell lymphoma should therefore target those early lymphoma precursor cells. PMID: 30808775 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Denileukin diftitox (DAB-IL-2, Ontak) is a diphtheria-toxin–based fusion protein that depletes CD25-positive cells including regulatory T cells and has been approved for the treatment of persistent or recurrent cutaneous T cell lymphoma. However, the clinical use of denileukin diftitox was limited by vascular leak toxicity and production issues related to...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Biological Sciences Source Type: research
More News: Cancer & Oncology | Cutaneous T cell lymphoma | Food and Drug Administration (FDA) | Grants | Lymphoma | Marketing | Pharmaceuticals | T-cell Lymphoma